# New Security Health Plan updates to commercial and exchange formulary

Security Health Plan may add rules about whether and when certain drugs are covered during the year. Your patients may not currently be using these products, but we want to provide you with these updates to alert you of any future changes.

Effective Oct. 1, 2023, for commercial and exchange lines of business:

- Taltz will be the preferred IL-17A inhibitor.
    - Coverage for Taltz will require a trial of ONE conventional treatment.
- Cosentyx will be the non-preferred IL-17A inhibitor.
    - Coverage for Cosentyx will require a trial of TWO preferred biologics indicated for the same condition.

These changes will not affect Medicare Advantage members.